International Agency for Research on Cancer (IARC) - Summaries & Evaluations
SULFAFURAZOLE
VOL.: 24 (1980) (p. 275)
5. Summary of Data Reported and Evaluation
5.1 Experimental data
Sulfafurazole was tested in mice and rats by oral administration: no
increases in tumour incidences were observed.
No adequate studies of mutagenicity were available.
It is teratogenic for mice and rats.
5.2 Human data
Sulfafurazole is one of the most commonly used sulfonamide drugs in
the treatment of urinary tract infections. Its production has remained
stable during recent years.
In one hypothesis-seeking epidemiological study, no association was
observed between sulfafurazole use and any cancer.
In two large studies of women exposed during pregnancy, no increase in
malformation rate was observed in the offspring.
5.3 Evaluation
The data from studies in experimental animals and in humans were not
indicative of a carcinogenic effect but were not sufficient for an
evaluation of the carcinogenicity of sulfafurazole to humans.
Subsequent evaluation: Suppl. 7 (1987)
Last updated: 7 April 1998